100 North Main Street
United States - Map
Targacept, Inc., a biopharmaceutical company, engages in the development of neuronal nicotinic receptors (NNR) therapeutics for the treatment of nervous system and gastrointestinal/genitourinary diseases and disorders. Its product candidates include TC-6499 for the treatment of diabetic gastroparesis; and TC-5619 and TC-6987, which are novel small molecules that are selective for the a7 NNR. The company was founded in 1997 and is based in Winston-Salem, North Carolina.
|Targacept, Inc.’s ISS Governance QuickScore as of Jul 1, 2014 is 6. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 8; Compensation: 5.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Stephen A. H. Hill B.M. B.Ch. M.A. F.R.C.S.,
Chief Exec. Officer, Pres and Director
|Ms. Mauri K. Hodges CPA, C.C.P.,
Chief Financial Officer, Principal Accounting Officer, VP of Fin. & Admin. and Treasurer
|Mr. Patrick C. Rock J.D.,
Sr. VP, Gen. Counsel and Sec.
|Dr. Jessica S. Beaver Ph.D., R.A.C,
Sr. Director of Regulatory Affairs and Quality Compliance
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|